Alliances
Roche and privately-held cell therapy company SQZ will jointly develop oncology products based on antigen presenting cells (APCs) that are created by the SQZ platform.
Joint optimization of groundbreaking resorbable medical device for treatment of full thickness wounds in oral cavities
Myriad to Provide BRACAnalysis CDx Testing in a Phase 2 Study Evaluating Talazoparib for Neo-adjuvant Treatment of Germline BRCA-mutated Triple Negative Breast Cancer
Exclusively licensed, rhabdovirus-free platform enables more productive bioprocessing
Bristol-Myers Squibb’s blockbuster checkpoint inhibitor Opdivo failed to meet endpoints as a treatment option for small cell lung cancer (SCLC) patients who relapsed following platinum-based chemotherapy.
Commercialization Plan Now in Place for BRACAnalysis CDx® As a Companion Diagnostic with Pfizer’s Talazoparib
Brii Biosciences is one of many China-based companies that are heavily investing in U.S. biotech and pharmaceutical companies to support the development of programs that could come back to China for approval.
Ionis Pharmaceuticals is on a roll. Days after securing regulatory approval from the FDA for Tegsedi, the company inked a deal worth more than $700 million with pharma giant Roche to develop IONIS-FB-L for the treatment of complement-mediated diseases.
Vitaccess and Pharnext SA today announced the launch of an international study on Charcot Marie Tooth disease (CMT) using a bespoke digital app named CMT&Me.
Ziopharm to Host Conference Call at 8 a.m.
PRESS RELEASES